Lexaria Bioscience Completes Dosing in Study Evaluating Next-Generation GLP-1 Drugs with DehydraTECH™

Kelowna, British Columbia — June 9, 2026 — Leads & Copy — Lexaria Bioscience Corp. announced the completion of dosing in its 2026 Animal Study #2 (GLP-1-A26-2), which is evaluating formulation enhancements for two next-generation glucagon-like peptide-1 (“GLP-1”) drugs. The study aims to explore the potential for improved performance of Lexaria's proprietary DehydraTECH™ platform and to establish new intellectual property claims.

The drugs under investigation are retatrutide, a leading GLP-1 drug developed by Eli Lilly and Company, and amycretin, owned by Novo Nordisk. Retatrutide is a triple hormone receptor agonist, targeting GLP-1, glucagon, and GIP receptors. Current Phase 3 studies for retatrutide in the weight loss market have shown significant results, with an average weight loss of 28.3%, or 70 pounds, for patients who remained on the drug. While retatrutide is currently administered via weekly injections, Lexaria's study will examine oral dosing in tablet and capsule forms. Retatrutide has not yet been approved by the FDA, but early results indicate a higher weight loss percentage compared to existing GLP-1 drugs on the market, with 65.3% of participants on a 12mg dose achieving a BMI below 30.

If successful, Lexaria's investigation into retatrutide could extend the applicability of DehydraTECH™ to future triple-agonist weight-loss peptide drugs that are in late-stage development and are expected to capture a significant portion of the market.

"This is a watershed moment for Lexaria’s investigations into GLP-1 drugs," said Richard Christopher, CEO of Lexaria Bioscience. "We have already established the compatibility of our technology with today’s leading GLP-1 drugs, but if we are likewise able to demonstrate benefits with the drugs of tomorrow like retatrutide, amycretin and others, then we will begin to show relevance to those drugs that will likely be on the market for the next 10 years or more."

Lexaria's comprehensive study includes 18 different arms to assess new DehydraTECH™ compositions. Blood samples are being collected at multiple timepoints over a 24-hour period post-dosing to quantify the pharmacokinetic (PK) performance of each composition. The study's primary objectives are to assess the compatibility of retatrutide and amycretin with DehydraTECH™ formulation and processing technology, focusing on PK performance and tolerability.

Common side effects associated with GLP-1 drugs, including next-generation retatrutide and amycretin, involve nausea and gastrointestinal issues such as diarrhea and vomiting. Lexaria's study aims to determine if DehydraTECH™ processing can reduce the severity and frequency of these side effects while maintaining or enhancing efficacy.

The study will also compare pill (tablet) formulations to capsules to better understand absorption differences, as most oral GLP-1 peptide drugs currently on the market utilize pill formulations primarily absorbed through the stomach. This research will compare alternative formulations to the salcaprozate sodium (SNAC) technology used in Novo Nordisk's oral Rybelsus® and Wegovy® products, including compositions utilizing sodium caprate, which is known to influence gastrointestinal absorption.

This study is self-sponsored and fully funded by Lexaria's existing corporate resources.

DehydraTECH™ is Lexaria's patented oral drug delivery formulation and processing technology designed to enhance drug absorption into the bloodstream. The technology has demonstrated the ability to increase bio-absorption, reduce side-effects, and improve the delivery of certain drugs across the blood-brain barrier. Lexaria operates a licensed in-house research laboratory and holds a significant intellectual property portfolio with 65 granted patents and additional pending applications globally.

Source: Lexaria Bioscience Corp.